EyePoint Pharmaceuticals, Inc. (FRA:PV3B)
12.10
+0.61 (5.31%)
At close: Dec 4, 2025
EyePoint Pharmaceuticals Revenue
EyePoint Pharmaceuticals had revenue of $966.00K USD in the quarter ending September 30, 2025, a decrease of -90.82%. This brings the company's revenue in the last twelve months to $42.34M, down -7.38% year-over-year. In the year 2024, EyePoint Pharmaceuticals had annual revenue of $43.27M, down -5.97%.
Revenue (ttm)
$42.34M
Revenue Growth
-7.38%
P/S Ratio
34.98
Revenue / Employee
$256.60K
Employees
165
Market Cap
1.26B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
| Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
| Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
| Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
| Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Rheinmetall AG | 11.00B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
EyePoint Pharmaceuticals News
- 16 days ago - EyePoint (EYPT) Receives Green Light to Proceed with Phase 3 DURAVYU Trials - GuruFocus
- 16 days ago - EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration - Wallstreet:Online
- 16 days ago - EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration - GlobeNewsWire
- 18 days ago - EyePoint (EYPT) Grants Stock Options to New Employees - GuruFocus
- 18 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Insider Sell: Ramiro Ribeiro Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) - GuruFocus
- 4 weeks ago - EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - GuruFocus
- 4 weeks ago - Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript - GuruFocus